SCHEMBL852747

SCHEMBL852747

CN(C(=O)c1c(O)c2ccccc2[nH]c1=O)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.55
MEN1 O00255 7/20 0.55
PGR P06401 1/20 0.55
KDM4E B2RXH2 10/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
NLRP3 Q96P20 1/20 0.54
RXFP1 Q9HBX9 1/20 0.53
ALDH1A1 P00352 3/20 0.52
MAPT P10636 2/20 0.52
GAA P10253 1/20 0.52
IDE P14735 1/20 0.51
MPI P34949 1/20 0.51
CACNA1B Q00975 1/20 0.51
APBA1 Q02410 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
RAB9A P51151 4/20 0.51
NPC1 O15118 3/20 0.50
KDM5A P29375 1/20 0.50
POLB P06746 1/20 0.50
PKM P14618 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11282853 0.92 KDM4E (0.52) KMT2AMEN1PGRKDM4ESMN1; SMN2
SCHEMBL9182411 0.92 KDM4E (0.52) KMT2AMEN1PGRKDM4ESMN1; SMN2
SCHEMBL11983217 0.90 KDM4E (0.50) KMT2AMEN1KDM4ESMN1; SMN2NLRP3
SCHEMBL11291469 0.90 KMT2A (0.50) KMT2AMEN1PGRKDM4ESMN1; SMN2
SCHEMBL11285148 0.89 KDM4E (0.50) KMT2AMEN1PGRKDM4ESMN1; SMN2
SCHEMBL9185831 0.88 MEN1 (0.49) KMT2AMEN1PGRKDM4EALDH1A1
SCHEMBL11983191 0.87 KDM4E (0.51) KMT2AMEN1PGRKDM4ESMN1; SMN2
SCHEMBL11983188 0.87 KDM4E (0.48) KMT2AMEN1PGRKDM4ESMN1; SMN2
SCHEMBL9186522 0.87 KDM4E (0.51) KMT2AMEN1KDM4ESMN1; SMN2NLRP3
SCHEMBL9182334 0.87 KMT2A (0.48) KMT2AMEN1PGRKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376456-A2 HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Actavis Group Ptc Ehf (IS) 2011-10-19 EP claimed
WO-2010070449-A2 HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ACTAVIS GROUP PTC EHF (IS) 2010-06-24 WO claimed
EP-0429627-B1 DERIVATIVES OF QUINOLINE-3-CARBOXANILIDE PHARMACIA AB REG NUMBER 556131 (SE) 1995-09-13 EP claimed
US-5310913-A Immunomodulators KABI PHARMACIA AKTIEBOLAG (SE) 1994-05-10 US claimed
EP-2432764-A1 SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS ClanoTech AB (SE) 2012-03-28 EP disclosed
EP-2376456-A2 HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Actavis Group Ptc Ehf (IS) 2011-10-19 EP disclosed
WO-2010133669-A1 SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS CLANOTECH AB (SE) 2010-11-25 WO disclosed
WO-2010133672-A1 DERIVATIVES OF QUINOLINE-3-CARBOXYLIC ACID AND THEIR MEDICAL USE CLANOTECH AB (SE) 2010-11-25 WO disclosed
WO-2010070449-A2 HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ACTAVIS GROUP PTC EHF (IS) 2010-06-24 WO disclosed
EP-0429627-B1 DERIVATIVES OF QUINOLINE-3-CARBOXANILIDE PHARMACIA AB REG NUMBER 556131 (SE) 1995-09-13 EP disclosed
US-5310913-A Immunomodulators KABI PHARMACIA AKTIEBOLAG (SE) 1994-05-10 US disclosed
EP-0429627-A1 DERIVATIVES OF QUINOLINE-3-CARBOXANILIDE. PHARMACIA AB (SE) 1991-06-05 EP disclosed
WO-1990015052-A1 DERIVATIVES OF QUINOLINE-3-CARBOXANILIDE PHARMACIA AB (SE) 1990-12-13 WO disclosed
EP-0059698-A1 Heterocyclic carboxamides, compositions containing such compounds, processes for their preparation and methods of treatment therewith AB LEO (SE) 1982-09-08 EP disclosed